Event-Driven Stocks

CEPHALON INC

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs7 good1 severedetails ↓

Financials

SEC XBRL · annual
 FY10FY09FY08
Revenue$2.81B$2.19B$1.97B
Operating income$717.6M$334.0M$184.5M
Net income$425.7M$342.6M$193.0M
Total assets$4.89B$4.66B
Total liabilities$2.05B$1.97B
Equity$2.63B$2.26B$1.42B
EPS (diluted)$5.27$4.41$2.54
Shares out.75.7M74.9M76.1M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2010
Operating margin
25.5%
Net margin
15.1%
Return on equity
16.2%
Return on assets
8.7%
Return on capital (ROCE)
19.5%
Liabilities / assets
42.0%
Debt / equity
0.78×
Book value / share
$34.78
Revenue growth (YoY)
28.2%
Net income growth (YoY)
24.3%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2010
Altman Z″ (distress)
3.75safe
Accruals / assets
7.3%clean
Piotroski F-Score
7/9strong

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
87
/ 100
Profitability 100Growth 100Catalyst 33Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

1 severe7 good
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating margin is positive
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Positive operating cash flow
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

FDA-approved drugs

openFDA · most recent
  • TREANDAMar 20, 2008
  • FENTORASep 25, 2006
  • TRISENOXSep 25, 2000
  • ACTIQNov 4, 1998
  • GABITRILSep 30, 1997
  • FENTANYLOct 4, 1993

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.